Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$DSCR: State Industrial Hemp Statutes
http://www.ncsl.org/research/agriculture-and-rural-development/state-industrial-hemp-statutes.aspx
- Go DSCR
$MEDT, $IDGC, $DSCR: "2 Of My Favorite Things Are Smoking A Pipe of Sweet Hemp & Playing My Harmonica" President Lincoln
$MEDT, $IDGC & $DSCR: Hemp the trillion dollar crop: Gregg Moseley-Clarke
$DSCR: Bill Clinton: How to create a TRILLION dollar industry!
BFSB real scammy feel on buyout @ .80.First time I notice class action suit settle even modestly for .07 increase bid.
http://biz.yahoo.com/e/111103/bfsb8-k.html
BFSB 1.15 second licks.......... what did I do to deserve just white glove service?
BFSB should be up 46 cents not down 46 cents at low of day
Need misreads of PR Board to enslave big fast panic grabs!!!!!!!!
BFSB 1.38 yikes condesention in some messages regarding giving away free money!!!!!
BFSB .99 holy misinterpretation of suspension from NAZ as totally false!!!!!
http://finance.yahoo.com/news/Brooklyn-Federal-Bancorp-Inc-prnews-681567154.html?x=0&.v=1
BFSB 1.73!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
BFSB 1.40 YIKES this can go to $3!
BFSB 1.275 working on upper levels of awesome.
BFSB (HOD) 1.19, this sight is awesome.
BFSB .98 HOD :this sight rocks hard!!!
Hi Old MMClubers NVDA if it gets past 20.50 it will see $23 to 25 within a week. good luck for a quick trade.
BFSB .59 love this site!!!
BFSB .55, this site is fun!!!!
YIKES BFSB .53. can it be this new improved site has its first winner????
Yikes found one by myself BFSB (.49)so ready with Brooklyn name and some coins to merge if another would just splurge????
Seriously GRAN nearly doubled on Bank merger..think this site should comb proable new candidates for coliding into $$$$$$$$$$$.
Need some Bank figure guys.I'll volunteer to scout for some Big Bank fry.
Its not the people its the site....Think I may moderate soon as all turned out lights!
Everything I said that would happen plus slightly more.
What went down????
REPR near double this site double rocks!!!!
What went down????
AMLJ mentioned here doubled!!!!
UVICF 4.20 but paid the 10% al along!
MALL 9.97 another near double this board rocks!!!!
AUD 1.0815 nice play!!!!
JBII Production Permit is due any day now........et z
JBII PR CONFIRMS THE FOLLOWING:
(1) Stack test done. Passed with flying colors.
(2) Islechem's findings confirmed -- clean "green" process. Emissions & residue non-hazardous.
(3) So clean, that no need for filters, oxidizers, or scrubbers (which would be normally required).
(4) This is a "green" light toward getting their permit. Next news up is permit and full scale commercial production taking FREE waste plastic by the ton and turning into high quality diesel fuel for a should be a massive gross profit per barrel.
JBII -- JBI, Inc. Receives Emissions Statistics for Plastic2Oil Processor
THOROLD, Ontario, Sep 17, 2010 (GlobeNewswire via COMTEX) -- JBI, Inc. (the
"Company") () announces the receipt of its P2O Stack Test Report performed by
Conestoga-Rovers and Associates ("CRA") on the Company's Plastic2Oil ("P2O") 20
metric ton commercial processor. The stack test, which is a measure of emissions
from the processor vent, was set up by CRA on August 16th and monitored by the
New York Department of Environmental Conservation ("DEC"), and completed on
August 17th.
The Company will file the stack test report with the DEC as part of its
application to obtain a simple air permit which will allow commercial operation
of the P2O processor.
The Company is pleased with these results, as they reaffirm Islechem's previous
findings that the operation of the P2O processor is a clean "green" process.
CRA's results indicate that the processor is emitting 14.87% oxygen to the stack,
while only emitting 3.16 ppm (parts per million) of carbon monoxide, 0.81 lb/hr
(86.4 ppm) of NOx, SO2 and THC were below 1 ppm, particulates tested below 0.02
lb/hr. In other words, the process puts a high percentage of oxygen back into the
air while emitting very little, if any, toxic substances during the conversion of
waste plastic into usable hydrocarbon fuels.
The stack test confirmed that the P2O processor emissions are below maximum
emissions allowed under a NYDEC simple air permit. Because of these results, the
Company believes it will not need to construct any filters, oxidizers or
scrubbers for the stack, which is directly connected to the processor through a
condenser to cool the air.
After the stack test, the P2O processor was shutdown to gather residue samples
from within the reactor for testing. The residue was tested and found to be well
below the TCLP thresholds for disposal in landfill. The residue from a P2O
processor can be shipped to landfill and is not considered a hazardous waste.
About JBI, Inc.
JBI, Inc. is a technology company focused on injecting intelligence into existing
products and processes, making them efficient and profitable. JBI seeks to
innovate new solutions to issues facing today's world, including environmental
concerns. JBI currently has four business lines including JBI's tape data
recovery, JAVACO, PAK-IT and our new Plastic2Oil business. Information on our
company and all of our products and services can be found at
http://www.jbiglobal.com.
Forward Looking Statements
This press release contains statements, which may constitute "forward-looking
statements" within the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act.
The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several
significant substantive changes affecting certain cases brought under the federal
securities laws, including changes related to pleading, discovery, liability,
class representation and awards fees as of 1995. Those statements include
statements regarding the intent, belief or current expectations of JBI, Inc., and
members of its management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such forward-looking
statements are not guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from those
contemplated by such forward-looking statements. Such risks include, but are not
limited to: (1) JBI has a history of net losses, and may not be profitable in the
future; (2) JBI may not be able to obtain necessary licenses, rights and permits
required to develop or operate our Plastic2Oil business, and may encounter
environmental or occupational, safety and health conditions or requirements that
would adversely affect its business; and (3) JBI may experience delays in the
commercial operations of its Plastic2Oil machines and there is no assurance that
they can be operated profitably.For a more detailed discussion of such risks and
other factors, see the Company's amended Annual Report on Form 10-K, filed on
July 9, 2010, with the Securities and Exchange Commission, and its other SEC
filings. The Company undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of unanticipated events
or changes to future operating results.
JBI, Inc. All rights reserved.
This news release was distributed by GlobeNewswire, http://www.globenewswire.com
SOURCE: JBI, Inc.
CONTACT: JBI, Inc.
Investor Relations
John Zervas
(877) 307-7067
jpz@jbi-ir.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
JBII additional must-read update from the New York State Department of Environmental Conservation:
From a friend of mine based on his conversation to the DEC. I've known him for around 10 years so I trust his info, and it's easily verifiable.
Additional info from the DEC:
1. JBII's process is a "completely green process" (their words)
2. They've never seen anything like it.
3. JBII will be the first and only ones in the country with anything like this.
4. The DEC is extremely excited to have a new industry born in New York and under their watch.
5. DEC expects no further hiccups going forward in getting the permit (their words).
6. They expect future permit applications to be a breeze in the state of New York (their words). They expect, but cannot promise of course, that getting permits in most other states will also be easy because most of them have similar criteria and can use their data.
7. The same guys from the DEC who have been on site working with them are the same guys who are involved with processing the application. They don't see anything wrong with the process or they themselves would ahve spotted it.
8. They expect NO comment period because the emission levels they expect in the report to be substantially below the levels that would require a comment period.
9. They have seen numerous others try and every single one of them fail to do what JBII is doing. None of them even made it to the stack test stage because they failed so miserably sooner whereas JBII not only made it, but preliminary data suggests they passed with flying colors.
JBII update from the New York State Department of Environmental Conservation...
My analysis:
=================
1. Stack test done and appears to have passed with flying colors!!!!
2. JBII appears very soon to be the first viable plastic-to-fuel company in North America with ZERO toxic fumes or substances.
3. PERMIT = Diesel fuel production and sales at a massive gross profit per gallon IMO!
The UPDATE:
=================
Posted by: Steady_T Date: Friday, September 03, 2010 9:16:15 PM
In reply to: righty who wrote msg# 68839 Post # of 68845
I talked to DEC this afternoon.
The stack test was conducted on Aug 17th.
Eyeball results of the data monitors as the data was collected was good. The final results will come back in reports after data analysis and data normalization.
The particulate test filters had nothing visible to the naked eye. That is way good.
3 different type of plastics were run. I didn't find out what they were.
DEC expects to receive the reports back very soon. There is a EPA annual reporting deadline coming up that is consuming much time for DEC and the labs that do the analysis. This happens every year. That may be why it has taken this long to get the reports back.
CRA and IsleChem are both involved in the permit application. There have been some people out on vacations.
DEC may require additional stack testing AFTER the permit is issued. They will decide that after the formal reports are presented in the application.
There were no issues raised by the stack test upon preliminary examination of the data.
My conclusion is that the application will be approved when submitted. The data suggests that the stack gasses look like a regular boiler gasses. The preliminary look at NOX, SOX, CO were that of a well controlled boiler.
Great news for REPR -- for those who are new, REPR's medical device is the preferred device and only at-home device approved and paid for by Medicare for this:
CSL Behring Receives FDA Approval To Extend Shelf Life Of Hizentra(R) From 18 Months To 24 Months
Article Date: 20 Aug 2010 - 2:00 PDT
CSL Behring announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to extend the shelf life of Hizentra®, Immune Globulin Subcutaneous (Human), 20% Liquid, from 18 months to 24 months. Hizentra, the first and only 20 percent subcutaneous immunoglobulin (SCIg) approved in the U.S. by the FDA, is also the first and only SCIg in the U.S. that may be stored at room temperature.
Hizentra is indicated for the treatment of primary immunodeficiency (PI). PI is a group of disorders, usually genetic, that result from a dysfunctional immune system. This condition prevents patients from fighting off infections caused by common germs.
Stabilized with L-proline, a naturally occurring amino acid, Hizentra can be stored at room temperature (up to 25°C [77°F]) for up to 24 months. Because no refrigeration is necessary, Hizentra is always ready to use without warming, offering patients and physicians convenience and portability.
"CSL Behring continually enhances the products in our broad portfolio based on what we know patients and their healthcare providers need and want," said Robert Lefebvre, Vice President and General Manager, U.S. Commercial Operations at CSL Behring. "The ability to store Hizentra without refrigeration for up to two years is an innovation that can positively impact busy and active patients managing their primary immunodeficiency at home or in any setting that is convenient for them."
The sBLA for Hizentra was based on a study assessing the product's stability. Physicochemical, biological and immunological parameters were assessed over 24 months' storage under controlled conditions at 25°C (77°F). The data generated from this study support that when Hizentra is stored at room temperature (up to 25ºC [77ºF]) and protected from light, it is stable for up to 24 months.
Hizentra with 24-month shelf life packaging is expected to be available later this year. Current Hizentra patients are encouraged to contact their physician with any questions regarding the shelf life of their current supply.
Hizentra is part of the immunoglobulin (Ig) franchise for CSL Behring. This comprehensive Ig product portfolio also includes the first U.S. FDA-approved subcutaneous immunoglobulin and the first proline-stabilized intravenous immunoglobulin. CSL Behring manufactures Hizentra at its state-of-the art facility in Bern, Switzerland, where advanced technologies are applied to further ensure product safety and ample supply. This facility represents the long-term commitment of CSL Behring to global Ig markets.
Important Safety Information
Hizentra®, Immune Globulin Subcutaneous (Human) is indicated for the treatment of patients with primary immunodeficiency (PI).
Hizentra is contraindicated in individuals with a history of anaphylactic or severe systemic response to immune globulin preparations or components of Hizentra, and in persons with selective immunoglobulin A deficiency who have known antibody against IgA and a history of hypersensitivity. If anaphylactic reactions are suspected, administration should be discontinued immediately and the patient treated as medically appropriate. Because Hizentra contains the stabilizer L-proline, it is also contraindicated in patients with hyperprolinemia.
The most common drug-related adverse reactions, observed in 5 percent or more of subjects in the clinical study, were local injection-site reactions, headache, vomiting, pain, and fatigue.
Monitor patients for reactions associated with IVIg treatment that might occur with Hizentra, including renal dysfunction/failure, thrombotic events, aseptic meningitis syndrome (AMS), hemolysis and transfusion-related acute lung injury (TRALI).
About Primary Immunodeficiencies
Nearly 150 types of PIs exist. For individuals with PI, many of them children, infections may not improve as expected with usual treatments and may keep returning. As a result, patients may face repeated rounds of antibiotics or hospitalization for treatment. Repeated infections can lead to organ damage, which over time can become life-threatening.
Collectively, PIs affect an estimated 10 million people worldwide, and the incidence is estimated to be 1 in 10,000. Due to the X-linked inheritance in many PI syndromes, more males are affected than females.
Source:
CSL Behring
CERP = NASDAQ stock forecasting massive growth and profitability
Some TIDBITS from their first conference call:
(1) 16 million pounds of bioplastic to be shipped in 2010. Guiding for sales could be $7 to $9 million for the 2nd half of 2010 or a +450% to +600% increase in sales. Forecasts operational profitability for Q4 with rapid growth in 2011.
(2) One contract alone is for $900,000 per month in sales beginning September 1.
(3) "The company and a large multi-billion dollar company....filed recently for a grant with the department of energy to fund a research project on our algae bio-plastic." Commercial use begins for algae bioplastic end of 2010 to early 2011.
(4) Pricing structure is now currently competitive to petroleum-based plastic.
(5) Current full capacity 80 million pounds of bioplastic = $100 million in sales per year. Goal is full capacity by 2012. Existing pipeline of clients suggest that deadline will be met [from them alone]. Thinks bioplastic market in general could top $10 billion by 2020.
(6) August 26 -- CERP rang the NASDAQ opening bell:
JBII 10Q out -- stack test this month (August)
Final step for permit application + commercial production + fuel sales at a massive profit per barrel
They have the parts for two more large scale processors.
Some REPR highlights from the 10Q that suggest a large jump in sales and profits coming IMO:
"hiring of a sales associate to promote the Freedom60 in Europe" <~~~~Daisy set???
"additional staff including two domestic sales associates"
"We believe the Freedom60 continues to find a solid following in the subcutaneous immune globulin market and with the introduction of a new 20% IgG drug released early this year, this market is expected to continue to increase both domestically and internationally."
"The Freedom60 use for Primary Immune Deficiency by injecting immune globulin (IgG) under the skin as a subcutaneous administration has seen increased usage especially in Europe over the past year and is expected to continue with the introduction a new 20% solution of IgG at the beginning of this year. We have been told by meeting users at trade shows that his method has provided them with vastly improved quality of life with much fewer unpleasant side effects over the traditional intravenous route."
"In May, we traveled to Ft. Lauderdale, FL for the INS: Infusion Nurses Society Annual Meeting and Industrial Exhibition; the largest meeting for infusion nursing professionals in the United States." <~~~~one of many recent trade shows
JBII = SEXIEST GREEN STORY I'VE EVER SEEN -- SLEEPING GIANT ABOUT TO WAKE UP IMO!
1. JBII is in the very final stages of getting a permit for their waste-plastic-to-oil technology at massive profit margins per barrel. Once permitted by the New York State Department of Environmental Conservation (who is working with them), JBII's machine is a license to print money. JBII's technology has been validated by and Islechem, a former business segment spun off Occidental Petroleum, a $60 billion NYSE company (NYSE: OXY):
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=49467137
2. JBII has a temporary permit to run this machine. The machine is running with tons of plastic successfully pouring in with fuel pouring out. There is a stack test "tentatively" scheduled. Successful passing of the stack test, which Islechem insists will be a walk in the park (zero toxic air emissions), is the final test before a permanent permit.
3. With this permanent permit, the money-printing machine will run 24/7 processing thousands of tons of plastic from everybody from Chrysler to Waste Management at a MASSIVE profit per barrel. JBII will then immediately start expansion via rapid duplication of processors for themselves and by JV partners (similar to a franchise model)
4. JBII will be the ONLY company in the world that's solving the plastic in landfill problem that not only uses a green clean technology, but it is MASSIVELY profitable (cost less expected to be eventually less than $10/barrel with a seemingly endless supply of FREE feedstock). Zero toxic air emissions, very little residue (which is non-toxic), extremely efficient, and self runs on natural gas, an off-gas byproduct of the fuel it creates. 2 man operation per shift. JBII will be promoted in the mainstream news. It's going to be a wild party.
5. This business model allows for easy and rapid expansion through duplication of putting machines across the country. Contract for 90+ machines already in place in Florida with Al Sousa, former executive of a multi-billion NYSE company.
6. JBII's P2O technology is green, zero pollution.
More JBII INFO:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=52521861
AMLJ visit 7/17/10 -- tidbits from my tour with CEO Jacob Inbar
(in no particular order other than going line by line from my notes which were mixed and out of order and I made no attempt to organize this info by I added a brief title to each number below)
(1) VISIT -- This was probably the most fascinating tour I've taken in all of my company visits. I was in simply in awe and felt like I was in a cheesey sci-fi movie only everything I was looking at was for real! Entire sections were "classified" and couldn't be shown much nor talked about. The place is kept extremely cold and sterile to avoid the chips these produce from getting contaminated. Most (all?) of their chips are so small they cannot be seen with the naked eye, and I had to view them with a microscope. There are microscopes everywhere and many areas resemble closer to a biotech lab. The manually-made chips are have to be assembled using the microscopes and extreme dexterity. After producing, each and every chip needs to be put through the most extreme of testing to mimic conditions in the real world far beyond anything possible. For example, some chips may be on an unmanned vehicle that starts in 105 degree heat and 60 seconds later is miles above the Earth in negative 60 degree cold. As such, there are liquid nitrogen tanks everywhere in the plant for the temperature shock machine that takes the chips from extreme heat to extreme cold in 3 seconds to make sure they still function 100% afterwards. This is just one example of the large number of testing stations each chip must go through.
(2) AUTOMATION -- They have two relatively new machines I was shown for automation in two different stages of production. The first one is a "wire bonder" which replaces six (6) people that cost on average $20/hour and runs 14 hours a day currently, steadily rising. Each product must be programmed into the machine which takes time. Jacob expects it will be programmed enough to run 20 hours a day within six (6) months and 24 hours a day three (3) months later. Around six (6) months from now he expects to buy and need a second wire bonder machine. They only cost $100,000 with a 20 year life so they pay for themselves very fast. Also, in addition to cost savings, their military customers absolutely love them as they have less (no?) chance of error and their precision is assured. In short, the machine is helping drive in new business. They are getting new orders daily. There's a big backlog on automated machine demand. They will be buying a painting & marking machine that automates that task. The other type of machine I forget the name of it but it is in a later stage of production and replaces 10 people. There will not be a need to get a second one of these for a while as it I believe works 24 hours a day and is quite efficient.
(3) MARKET & COMPETITION -- As many of you already know, AMLJ operates in a niche market place that's "growing fast" -- to quote Jacob, "We didn't know there was a recession." The unmanned military vehicle market is their biggest market. Only two competitors they have are Miteq, a private company. And a tiny division of Teledine which has around $25 million in sales per year. New competitors emerging = zero threat. Their barriers to entry are extreme. It takes many years to build a company like this and even more time to build the trust and relationships necessary to deal with such high level of classified military applications. Jacob sees zero reasonable competitive threats any time soon even trying to emerge.
(4) NATURE OF THEIR BUSINESS -- Develop for then produce. As such, sales tend to be flat for 1-3 quarters then they see you a boost in a steady stair-step-like fashion. My own comments -- sales been flat the last 3 quarters. This a hint about the upcoming Q report???
(5) CAPACITY -- Capacity of $70 million in the current facility(ies). He showed me how little space the products take up by showing me a case of the "work in progress" inventory. It was the size of a gym bag. He said this is around $50,000 of product for today alone (a Saturday or did he mean a typical business day? dunno). The workers work 8 hours a day Monday to Friday with 1-2 hours over time typical of most of them. And they are open for around 4 hours on Saturdays doing production. I was there after the Saturday shift. There were still a few workers there when I left which was 3 hours after the shift was over. Over time maybe? The automated machines were churning. When I pushed about capacity if he thinks it was possible to reach that and what they would do at that point, he told me he thought it was very possible and as a stockholder what they would do at that point should be the least of my worries because the stock price could be $20 at that point. Please note, this is a casual off-the-cuff remark half-joking as a result of my pushing and not in any way a forecast even remotely. Going forward they are NOT hiring production staff. They will only expand via automation. My own thoughts -- the margins on these must be extreme as most of their COGS is employee expense whereas automation expansion must have almost no expense. I'm going to get gross profit at 90% at the least.
(6) CUSTOMERS -- Sales are 40% orders to their catalog, 60% to "the big guys" (the multi-billion dollar military companies like Northrop Grumman, etc.). International sales are around 25% with a lot of them to France ("believe it or not") and South Korea.
(7) NEW PRODUCT LINE -- New line of product hinted about in the conference call -- it's been in development for 6 months. They expect to announce it with the November conference call and follow it with a detailed press release. It's a very exciting high tech military area for them. They figured they already have all of these huge customers and a high rep with military applications so why not give them new products to buy? It will be an easy sell. The expenses for this area have been quietly absorbed in the last two reports so there's little to no risk. This area will be launched -- not a matter of if but when. They are particularly excited about this. Marketing expenses are CHEAP. Their customers come to them. They do very little selling. Their reputation sells it self though they expect to do some heavy marketing in the first 3 months after this product line is launched he doesn't expect you'll be able to notice it in the financials as the costs will be absorbed by further efficiencies in other areas.
(8) CASH -- Cash position -- it's growing and they don't know what to do with it. They will continue to invest in automation areas and make acquisitions in combination of stock and cash but prefer not all cash because stock keeps the target motivated to do well whereas a cash acquisition could make them lazy. Incentive is important. Their other facility was an acquisition a few years ago and is so self sufficient and producing steady cash for them that they need little management.
(9) JACOB'S BACK ROUND -- Born in Romania, lived in Israel for 15 years. Was in the Israeli army for 3 years. Eventually moved to the USA. Formed CalAmp in 1981. Left in 1986 selling most of his stock to form AMLJ along with two co-founders. My own comments -- Jacob has a bit of a monotone and is boring on the CC, but in person he comes off as an extremely suave, charismatic, confident, and really energetic & enthusiastic businessman.
(10) EXIT STRATEGY -- When I asked about exit strategy he said he's not ready to retire for at least another 10 years as he loves what he does, however, if the right price came along they could be bought out. He said they've had interest before but he demands a large premium for buyout, but he wouldn't be surprised if they do end up getting bought out at some point. In the mean time, he and other management own 30% of the outstanding shares with no plans (by Jacob) to sell any of his shares any time soon.
JBII CONFERENCE CALL TIDBITS OF INTEREST:
PLASTIC-TO-OIL:
(1) Stack test now scheduled which takes one day -- last step to get the permit to start full commercial operations.
(2) JBII's technology improved the fuel yield to 89% from 40%.
(3) Off-gas byproduct is produced and self-runs the system with excess natural gas that's stored as a bonus.
(4) 2 man operation per shift. Process is simple and robust with very little waste. Total cost of the processor only $200,000.
(5) Entire process is being patented. No more changes needed.
(6) Free feedstock already lined up. Plenty of sources available. "We can be choosey at this time" because there's so much available.
Prefers hydrocarbon-based plastic from industrial waste which tends to maximize the numbers out of the processor.
(7) Permit = immediate full commercial operations including sale of already produced fuel.
(8) Permit = joint-venture partnerships begin talks for expansion everywhere.
PAKIT:
(1) "Commercials expected launch this summer"
(2) "We look forward to announcing the new product line in the very near future"
CC Replay: http://www.investorcalendar.com/IC/CEPage.asp?ID=160560
REPR visit -- 7/9/10
I visited REPR and took a tour. I didn't gain much insight on the next earnings report, but here is some of what I found particularly interesting. Met with Barry Short, Director of Administration for nearly 2 hours and the CEO Andy for a brief moment.
In no particular order...
(1) Daisy needle set FDA approval is still pending. They are in active back and forth discussion with the FDA giving them constant data feedback. The approval will come but timing is near impossible to predict as they move at a snail's pace. Upon approval they expect a significant sales jump, though they cannot promise anything of course, they expect the approval has no realistic chance of rejection but the FDA wants seemingly endless amounts of data first.
(2) Daisy set has been approved in other places around the world already. Sales to Europe for the Daisy set are being shipped this month.
(3) They think/hope the drug approval for Hizentra in March will be a significant sales/earnings boost as it allows the quality of life to be much improved for the patient and should significantly increase the number of people who choose to administer the drug at home vs. the hospital since it requires far less needle sticks. Also CSL Behring is pushing the Freedom 60 in their sales efforts which is nice for REPR to have somebody else basically advertising for them for free. They do note that new approvals like this one take time for awareness to spread and patients to switch to the new preferred drug (and to REPR's FREEDOM 60)
(4) Tour observations -- relatively simple, efficient, assembly line low-skilled labor. They seem to make and sell the tubing sets more than anything which I was happy to see since the price they charge for tubing sets has gone up 20% recently.
(5) Res-Q-Vac is being marketing to coincide with the grant funding schedules of various institutions for the first time this year. There's a bigger push than normal to sell them. There's a new marketing flyer for the RES-Q-VAC to hurricane risk areas that is a first marketing strategy for them. I will scan and post the flyer some time this week.
(6) The CEO Andy mentioned he was very busy working on the 10Q. I would like to think it's human nature to not even mention that unless you expect it to contain good news.
(7) International marketing strategy includes signing only one master distributor per country to have a distribution monopoly on the Freeom 60 or RES-Q-VAC to give them incentive to advertise within that country without fear of competition from other distributors. Also they are seeing and/or expect a pickup in sales from developing countries whose power supply is often unreliable and the Freedom60 and RES-Q-VAC both work without electricity except for a battery for the new light wand on the RES-Q-VAC.
(8) The RES-Q-VAC now comes with a bendable battery-operated light wand.
(9) They are "constantly expanding" and as such always hiring or taking applications and expect with the Daisy approval they'll need to hire a significant number of new workers as they already have orders lined up waiting for approval.
(10) More trade shows are coming this year in addition to the ones already attended which in the past tends to lead to new customers.
INTT = Huge turnaround play heading for double digits IMO.
INTT swung deep into profitability of +.11 EPS last Q.
I'm expecting up to triple that next Q. Here's why:
(1) Conference call noted bookings one Q = sales the next.
Bookings end Q1 = $14 million.
Sales of $14 million = +200% YOY jump and 46.9% sequential.
(2) CC notes indicate:
"to be conservative" -- 35% material cost + 5% sales comission = 40%
"theoretically 60% of incremental revenue drops to the bottom line"
Doesn't expect SG&A to go over $4 million per Q for rest of year.
Do the math -- realistic +.33 EPS pre-tax or more.
(3) +.33 EPS annualized = $1.32 per share which is just insane for a stock price this cheap.
INTT could run wild into the double digits per share on earnings and/or pre-announcement of earnings.
$10 to $15 coming IMO and well over $20+ very possible.
(4) Here's an article forecasting +.31 EPS: http://seekingalpha.com/article/204847-intest-earnings-conference-call-confirms-positive-view
(5) 72 year old chairman has a stock trading program for his retirement that refuses to sell any shares under $8.00 per share before even a portion of them can be sold then with requirements of higher share prices for more sales:
http://finance.yahoo.com/news/inTEST-Corporation-Executive-prnews-2524294056.html?x=0&.v=1
(6) The industry itself is going absolutely nuts. What's in store for INTT for Q3 and beyond? .50 EPS quarters or a $2 annualized pace? Pick whatever fair PE ratio you can dream of and you get a massive turn from here.
Caught with Their Chips Down
A worldwide shortage of key components is squeezing bottom lines
http://www.businessweek.com/archives/2000/b3683086.arc.htm
Here is an EE Times article that indicates that Samsung may have as much as a 50% growth in IC sales this year and is spending $9.6B on semiconductor capital.
http://www.eetimes.com/news/latest/showArticle.jhtml;jsessionid=UUPFRW30GRTMRQE1GHRSKH4ATMY32JVN?articleID=225200502
Update: LEDs in short supply as market booms
http://www.eetimes.com/showArticle.jhtml;jsessionid=UUPFRW30GRTMRQE1GHRSKH4ATMY32JVN?articleID=224900102
Analog vendors turning away business
http://www.eetimes.com/showArticle.jhtml;jsessionid=UUPFRW30GRTMRQE1GHRSKH4ATMY32JVN?articleID=224700545
Here is an interesting interview on semiconductor demand:
http://www.cnbc.com/id/15840232/?video=1512561683&play=1 <~~~ Biggest fundamental jump in demand not seen since the mid-1990s!!!
Semiconductor Equipment Spending To Double In 2010
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=51130928
REPR = home run biomed stock in the making IMO
1. Earnings out...
Sequentially for the Q:
Record sales +25%
Record operating income +268%
Record earnings +444% to +.01 EPS
Next Q due July 15.
I think REPR is well on its path to getting +.02/+.03 quarters in earnings
Translates to +.08/+.12 EPS annual pace, $1.00 - $2.00 potential target.
Lots of goodies in the 10K. A sample of them below.
2. How To Get To .02/.03 EPS Per Quarter
Gotta increase net income by $350k to $700k.
How to do that:
(1) Gross profit margins are now 70% and growing.
http://finance.yahoo.com/q/is?s=REPR.OB
I happen to be a huge fan of large GPM because it means rapid EPS growth with small upticks in sales. For example, notice how operating income TRIPLED (+200%) with a mere 24% increase in sales.
(2) Notice how SG&A has been flat to down even while sales increase. This means that increases in gross profit go straight to the bottom line.
(3) So in order to get a $350k to $700k increase in pre-tax income, we need $500k to $1 million increase in sales.
(4) With a 2nd shift in production, a new drug approved, and all of the recent tidbits spelled out in the 10K for sales growth, I think it is reasonable to see a 45-90% increase in sales over last quarter.
3. Tidbits from the 10K...
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7290970
Price increase:
"In the past we marketed the pump priced at a discount to promote sales of tubing sets. We now market pumps at fair market value."
"During January 2010, a new subcutaneous immune globulin called Hizentra(R) with a greater concentration was approved by the FDA. We have performed significant testing of the new drug with the Freedom60 and have been approved by the drug company for use with their drug. Based on initial reactions, the new formulation appears to be an improved drug at higher concentrations, and is expected to replace the previous offerings."
"We anticipate these sales to continue to increase as the SCIG market continues to develop and as we work on new enhancements to the Freedom60 that we believe will expand this market even further. In addition, we expect many of the SCIG users will see benefit in using the Freedom60 system for other uses, such as antibiotics, chemotherapeutics and pain medications."
"We have been developing our own needle administration sets for subcutaneous immune globulin, which incorporates many enhanced features that we believe will address many of the issues faced by current offerings. Due to the introduction of Hizentra with its increased viscosity, the new needle administration sets were designed with improved flow characteristics. Our new needle set design has very low fluid resistance creating the ability for rapid administrations with improved safety. As mentioned previously, we are negotiating with FDA and plan to submit an FDA 510(k) application for the new set and updated performance features of the Freedom60."
"Additional new markets we have recently sold include schools and hospital-based respiratory centers. We are also planning mailings into those markets. In the school market, we have been informed that any school with a swimming pool is normally required to have suction equipment available. In addition, many schools are installing automatic electronic defibrillators (AED's) for which suction is mandatory in more than 50% of uses for this device."
4. REPR, being a biomedical stock, is largely unaffected by a negative economy. Their core product, the Freedom60, is the only device in his market approved by Medicare as it actually is a much cheaper alternative to anything out there and much safer.
From Medicare letter: "The Freedom60 Syringe Infusion Pump is the only allowable pump to be billed with the Subcutaneous Immune Globulin (SCIG)"
JBIIE = SLEEPING GIANT ABOUT TO WAKE UP
1. JBIIE's machine is a license to print money via its waste plastic-to-fuel process which has been validated by Islechem, a spawn of a $70 billion NYSE company (NYSE: OXY).
http://finance.yahoo.com/news/JBI-Inc-Announces-That-pz-1245470791.html?x=0&.v=1
2. JBIIE has a temporary license to run this machine. The machine is running with tons of plastic successfully pouring in with fuel pouring out.
3. JBIIE is DAYS AWAY from a permanent license. With this permanent license, the money-printing machine will run 24/7 processing thousands of tons of plastic from everybody from Chrysler to Waste Management at a MASSIVE profit per barrel.
4. JBIIE will be the ONLY company in the world that's solving the plastic in landfill problem that not only uses a green technology, but it is MASSIVELY profitable (cost less than $10/barrel with a seemingly endless supply of feedstock). JBIIE will be promoted in the mainstream news. It's going to be a wild party.
5. This business model allows for easy and rapid expansion through duplication of putting machines across the country. Contract for 90+ machines already in place in Florida with Al Sousa, former executive of a multi-billion NYSE company.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=50054304
JBII RECENT PRs GROUPED
P20 LICENSES
Contract for 45 sites in Florida:
http://finance.yahoo.com/news/JBI-Inc-Executes-Area-pz-2488167028.html?x=0&.v=1
P2O reservation deposit for Tampa, Florida:
http://finance.yahoo.com/news/AS-PTO-LLC-Accepts-pz-1206567454.html?x=0&.v=1
P2O reservation deposit for Clearwater, Florida:
http://finance.yahoo.com/news/AS-PTO-LLC-Enters-Into-pz-1883257357.html?x=0&.v=1
P2O reservation deposit for Cleveland, Ohio ara:
http://finance.yahoo.com/news/Ohio-P2O-LLC-Submits-a-pz-2239196307.html?x=0&.v=1
Nine Other States being evaluated in addition to Florida plus taking applications for more:
"JBI is also evaluating candidates for areas of Virginia, Washington, DC, Ohio, California, Arizona, Oregon, Georgia and Wisconsin"
http://finance.yahoo.com/news/JBI-Inc-Begins-Taking-pz-4196081035.html?x=0&.v=1
P20 Ships For Global Expansion:
http://finance.yahoo.com/news/JBI-Incs-P20-Marine-Inc-Rick-pz-1364554894.html?x=0
ACQUISITIONS
Fuel blending & distribution site with a $300 million capacity:
http://finance.yahoo.com/news/JBI-Inc-Acquires-Large-pz-416916477.html?x=0&.v=1
New York Processing Facility to serve as a company owned P2O site:
http://finance.yahoo.com/news/JBI-Inc-Acquires-New-York-pz-2604180689.html?x=0&.v=1
U.S. Air Filtration Company and custom air ventilation company (profitable):
http://finance.yahoo.com/news/JBI-Inc-Executes-Letter-of-pz- 3617226092.html?x=0&.v=1
NEW HIRES
JBI, Inc. Hires Four Seasoned Sales Reps for Pak-It Canada Launch:
http://finance.yahoo.com/news/JBI-Inc-Hires-Four-Seasoned-pz-4011247930.html?x=0&.v=1
JBI, Inc. Hires Experienced Ship Captain Michael Moneyhan to Oversee P2O Ship Expansion:
http://finance.yahoo.com/news/JBI-Inc-Hires-Experienced-pz-3900158860.html?x=0&.v=1
JBI, Inc. Hires Michael Kaplanis as Vice-President, Mergers & Acquisitions and Strategy:
http://finance.yahoo.com/news/UPDATING-and-REPLACING-JBI-pz-3685863318.html?x=0&.v=1
New Board of Directors
John M. Wesson:
http://finance.yahoo.com/news/JBI-Inc-Appoints-John-M-pz-3527337080.html?x=0&.v=1
Amy Bradshaw:
http://finance.yahoo.com/news/JBI-Inc-Appoints-Amy-Bradshaw-pz-190242946.html?x=0&.v=1
Theodore J. Henry:
http://finance.yahoo.com/news/JBI-Inc-Appoints-Theodore-J-pz-3461545571.html?x=0&.v=1
Dr. Jacob Smith:
http://finance.yahoo.com/news/JBI-Inc-Appoints-Chief-pz-1058916790.html?x=0&.v=1
OTHERS
JBII Goes to Washington To Discuss P2O With Congressmen:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=46632073
IsleChem, name of the state-certified independent lab, is running and analyzing a JBII P2O processor:
http://finance.yahoo.com/news/JBI-Inc-IsleChem-pz-1168652688.html?x=0
JBII CEO invited as guest speaker at African Petroleum Producers Association Event:
http://finance.yahoo.com/news/JBI-Inc-CEO-Will-be-a-Guest-pz-3294028247.html?x=0
Shareholder meeting 4/24/10:
http://finance.yahoo.com/news/JBI-Inc-Sets-Annual-pz-1608897935.html?x=0
JBII -- Nasdaq Uplisting filed: John Bordynuik : I already filed the NASDAQ application and wired the $5000 fee.
P-O-W-R @6.31 new close fav.............................must play with it to sqeeze all friskies out........Yikes I love this jumping jack, just a generous piece of no brain glitter with an almost daily hair trigger.
Hope for all sake no one reads this post, as i want it for me-slf.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |